<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>http://hboevidence.wikis.unsw.edu.au/index.php?action=history&amp;feed=atom&amp;title=Bojic</id>
	<title>Bojic - Revision history</title>
	<link rel="self" type="application/atom+xml" href="http://hboevidence.wikis.unsw.edu.au/index.php?action=history&amp;feed=atom&amp;title=Bojic"/>
	<link rel="alternate" type="text/html" href="http://hboevidence.wikis.unsw.edu.au/index.php?title=Bojic&amp;action=history"/>
	<updated>2026-10-05T20:16:00Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.31.0</generator>
	<entry>
		<id>http://hboevidence.wikis.unsw.edu.au/index.php?title=Bojic&amp;diff=32&amp;oldid=prev</id>
		<title>Gordoben: Imported from Wikispaces</title>
		<link rel="alternate" type="text/html" href="http://hboevidence.wikis.unsw.edu.au/index.php?title=Bojic&amp;diff=32&amp;oldid=prev"/>
		<updated>2018-05-04T02:12:19Z</updated>

		<summary type="html">&lt;p&gt;Imported from Wikispaces&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 130%;&amp;quot;&amp;gt;'''Hyperbaric oxygen transiently improves visual fields in open-angle glaucoma in a dose-dependent manner.''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Clinical Bottom Line:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1. Hyperbaric oxygenation improves visual field but not intra-ocular pressure in open-angle glaucoma. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;2. Improvement in fields is shown to ameliorate over six months following treatment. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;3. Improvement was dose-dependent over the range 10-30 treatments. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Appraised by:''' Mike Bennett, Dept of Diving and Hyperbaric Medicine, Prince of Wales Hospital, Sydney; Tuesday, 19 January, 1999 &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Clinical Scenario:''' A patient with open-angle glaucoma and restricted visual fields. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Three-part Question:''' In chronic open-angle glaucoma, does the application of hyperbaric oxygen compared to normobaric air, result in any improvement in visual fields, visual acuity or intra-ocular pressure? &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Search Terms:''' Hyperbaric oxygenation, glaucoma &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''The Study:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Double-blinded randomised controlled trial with intention-to-treat. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Patients with primary open-angle glaucoma taking regular medication to reduce intra-ocular pressure. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Control group (N = 20; 20 analysed): Usual care with sham treatment at 2ATA breathing 10.5% oxygen to simulate normal air breathing. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;Experimental group (N = 91; 91 analysed): Usual therapy plus oxygen at 2ATA for 90 minutes daily for 10 (n=20), 15 (n=20), 20 (n=20) and 30 treatments (n=31)(5 days/week). &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''The Evidence (using 30 treatment group example):''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''Non-Event Outcomes Time to outcome Before HBO After HBO P-value''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''Blind spot (cm2)''' 6 weeks 0.76 0.52 &amp;lt;0.05 &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''Blind spot (cm2)''' 6 months 0.76 0.6 &amp;gt;0.05 &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''Visual field''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''Isopter4 (cm2)''' 6 weeks 123 135 &amp;lt;0.05 &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''Visual field''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 110%;&amp;quot;&amp;gt;'''Isopter4 (cm2)''' 6 months 123 131.5 &amp;gt;0.05 &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Comments:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1. There were no significant changes in visual acuity or intra-ocular pressure across the groups. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;2. The two groups were not compared directly, rather they were each compared with their own pre-treatment baseline. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;3. There were no statistically significant changes in the control group in terms of fields, blind spot or pressure. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;4. The changes in visual field and blind spot areas before and after hyperbaric oxygenation remain statistically significant at 3 months, but not six months. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;5. Reduction in blind spot area and improvement in visual field were dose dependent, becoming non-significant at 10 treatments compared to control. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;6. The authors recommend 20 treatment course with re-treatment as required. &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''Expiry date:''' April 2021&amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;'''References:''' &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;1. Bojic L, Racic G, Gosovic S, Kovacevic H. The effect of hyperbaric oxygen breathing on the visual field in glaucoma. Acta Ophthalmologica 1993; 71:315-319. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;2. Bojic L, Kovacevic H, Andric D, Romanovic D, Petri N. Hyperbaric oxygen dose of choice in the treatment of glaucoma. Arh Hig Rada Toksikol 1993; 44:239-247. &amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;font-family: Arial,Helvetica,sans-serif; font-size: 120%;&amp;quot;&amp;gt;3. Bojic L, Kovacevic H, Gosovic S, Denoble P. The effect of hyperbaric oxygen on glaucoma: a prospective study. In: Bakker DJ, Schmutz J, eds. Hyperbaric Medicine Proceedings, 2nd Swiss Symposium on Hyperbaric Medicine. Basel, Switzerland 1990:273-275. &amp;lt;/span&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[File:sumhorsa.gif|center|sumhorsa.gif]]&lt;br /&gt;
&lt;br /&gt;
&amp;lt;span style=&amp;quot;background-color: #ffffff; color: #7c00ff; display: block; font-size: 26px; text-align: center;&amp;quot;&amp;gt;'''[[Ophthalmology  |  BACK]]'''&amp;lt;/span&amp;gt;&amp;lt;span style=&amp;quot;background-color: #ffffff; display: block; text-align: center;&amp;quot;&amp;gt;&lt;br /&gt;
&amp;lt;/span&amp;gt;&lt;br /&gt;
&amp;lt;span style=&amp;quot;color: #7c00ff; display: block; font-family: arial,helvetica,sans-serif; font-size: 26px; text-align: center;&amp;quot;&amp;gt;&lt;br /&gt;
&amp;lt;/span&amp;gt;&lt;/div&gt;</summary>
		<author><name>Gordoben</name></author>
		
	</entry>
</feed>